Summit Therapeutics (SUMM) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Summit Therapeutics: Major Upcoming Ivonescimab Data Catalyst May Not Be All It Seems (Rating Downgrade)March 28, 2025 | seekingalpha.comCantor Fitzgerald Initiates Coverage of Summit Therapeutics (SMMT) with Overweight RecommendationMarch 22, 2025 | msn.comSummit rises as Cantor becomes latest to launch with a bullish viewMarch 21, 2025 | msn.comSummit Therapeutics names Robert LaCaze as Chief Commercial OfficerMarch 18, 2025 | markets.businessinsider.comEvercore ISI Group Initiates Coverage of Summit Therapeutics (SMMT) with Outperform RecommendationMarch 12, 2025 | msn.comSummit Therapeutics initiated with an Outperform at Evercore ISIMarch 12, 2025 | markets.businessinsider.com2025 CAMPS Summit Selects Merakris Therapeutics’ Scientist with Inaugural “Best Comparative Trial” AwardMarch 4, 2025 | finance.yahoo.comGoldman Sachs Initiates Coverage of Summit Therapeutics (SMMT) with Buy RecommendationMarch 1, 2025 | msn.comGoldman Sachs Initiates Coverage of Summit Therapeutics (SMMT) with Buy RecommendationMarch 1, 2025 | msn.comSummit Therapeutics initiated with a Buy at Goldman SachsFebruary 28, 2025 | markets.businessinsider.com1SMMT : Summit Therapeutics's Options Frenzy: What You Need to KnowFebruary 27, 2025 | benzinga.comSummit Therapeutics Inc. (SMMT): Among the Stocks That Will Go to the Moon According to AnalystsFebruary 27, 2025 | msn.comSummit Therapeutics’ Earnings Call Highlights: Collaborations and Clinical ProgressFebruary 25, 2025 | tipranks.comSummit Therapeutics Inc. (NASDAQ:SMMT) Q4 2024 Earnings Call TranscriptFebruary 25, 2025 | msn.comWhy Summit Therapeutics Inc. (SMMT) Went Down On Monday?February 25, 2025 | msn.comQ4 2024 Summit Therapeutics Inc Earnings CallFebruary 25, 2025 | uk.finance.yahoo.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Immunovant (IMVT), Summit Therapeutics (SMMT) and Outset Medical (OM)February 25, 2025 | markets.businessinsider.comSummit Therapeutics, Pfizer to Study Ivonescimab/ADC CombosFebruary 25, 2025 | marketwatch.comSummit Therapeutics Reports 2024 Financials and ProgressFebruary 24, 2025 | tipranks.comSummit Therapeutics Shares Down as 4Q Loss WidensFebruary 24, 2025 | marketwatch.comWhy Summit Therapeutics Inc. (SMMT) Is Among the Best Healthcare Stocks To Buy According to AnalystsFebruary 8, 2025 | msn.comSummit Therapeutics (SMMT): Jim Cramer Calls It a ‘Very Big Spec’February 3, 2025 | msn.comWhy Summit Therapeutics (SMMT) Is Skyrocketing NowJanuary 26, 2025 | msn.comSummit Therapeutics announces executive compensation changesJanuary 24, 2025 | msn.comMitchell Kapoor Reaffirms Buy Rating for Summit Therapeutics Citing Promising Phase 3 Drug Candidate IvonescimabJanuary 21, 2025 | markets.businessinsider.comSummit Therapeutics (SMMT) Gets a Buy from JefferiesJanuary 17, 2025 | markets.businessinsider.comLooking At Summit Therapeutics's Recent Unusual Options ActivityJanuary 17, 2025 | benzinga.comSummit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 7, 2025 | finance.yahoo.comNAYA Biosciences Announces Development of NY-500, a Novel AI-Optimized PD-1 x VEGF Bifunctional AntibodyJanuary 6, 2025 | markets.businessinsider.comThe Play On Summit TherapeuticsJanuary 5, 2025 | seekingalpha.comSouth Florida company stocks beat the Dow in 2024January 4, 2025 | bizjournals.comDrug-Trial Results Could Shake Up Pharma Stocks in 2025. Watch Eli Lilly, Pfizer, and More.January 1, 2025 | msn.comHere are Morgan Stanley’s key oncology catalysts for 2025December 28, 2024 | msn.comSerina Therapeutics to Present at LNP SummitDecember 12, 2024 | markets.businessinsider.comWells Fargo Initiates Coverage of Summit Therapeutics (SMMT) with Overweight RecommendationDecember 12, 2024 | msn.comChemomab to Participate in Oppenheimer’s Movers in Rare Disease SummitDecember 3, 2024 | markets.businessinsider.comRakovina Therapeutics Announces Presentation at the 13th Annual Tumour Models London SummitDecember 3, 2024 | markets.businessinsider.comSummit Therapeutics (SMMT) Hurt Bronte Capital. Here’s WhyNovember 20, 2024 | msn.comAN2 Therapeutics to Participate at Upcoming Investor ConferencesNovember 14, 2024 | finance.yahoo.com4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIVNovember 14, 2024 | finance.yahoo.comIRLAB to Present at BioStock Life Science Summit 2024November 13, 2024 | finance.yahoo.comSpur Therapeutics to Participate in B. Riley Securities’ Next-Gen Tissue Delivery Modalities Virtual SummitNovember 7, 2024 | finance.yahoo.comStifel Nicolaus Keeps Their Buy Rating on Relay Therapeutics (RLAY)November 7, 2024 | markets.businessinsider.comJMP Securities Initiates Coverage of Summit Therapeutics (SMMT) with Market Outperform RecommendationNovember 5, 2024 | msn.comFoghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate UpdateNovember 4, 2024 | finance.yahoo.comSummit Therapeutics Leads The Parade Of Big GainersNovember 4, 2024 | forbes.comSummit Therapeutics initiated with an Outperform at JMP SecuritiesNovember 4, 2024 | markets.businessinsider.comSummit Therapeutics Advances NSCLC Trials and Strengthens FinancialsNovember 1, 2024 | markets.businessinsider.comPromising Results from Atossa Therapeutics’ I-SPY 2 Study Lead to Buy Rating for Z-endoxifen in Breast Cancer TreatmentOctober 31, 2024 | markets.businessinsider.comPromising Phase 1/2 Trial Data Boosts Buy Rating for Lexeo Therapeutics’ Alzheimer’s Drug LX1001October 31, 2024 | markets.businessinsider.com Remove Ads Get Summit Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SUMM and its competitors with MarketBeat's FREE daily newsletter. Email Address SUMM Media Mentions By Week SUMM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SUMM News Sentiment▼0.610.61▲Average Medical News Sentiment SUMM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SUMM Articles This Week▼02▲SUMM Articles Average Week Remove Ads Get Summit Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SUMM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AstraZeneca News Today GSK News Today Haleon News Today NIOX Group News Today Beximco Pharmaceuticals News Today Smith & Nephew News Today ConvaTec Group News Today Hikma Pharmaceuticals News Today HUTCHMED News Today Genus News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:SUMM) was last updated on 4/5/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Summit Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Summit Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SUMM Stock Free SUMM Stock Alerts